ClinicalTrials.gg
Sign In
CompletedNCT00136201Updated Jul 7, 2009

Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections

A Phase 3 interventional study of tigecycline in Abdominal Abscess, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-07.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to compare the safety and efficacy of an experimental antibiotic to a marketed antibiotic in the treatment of Chinese subjects with complicated intra-abdominal infections. \<br />

02

Conditions studied

  • Abdominal Abscess

Keywords

  • Peritonitis
  • Community-Acquired Infections
  • Cross Infection
03

In context

Abdominal Abscess

31 studies on the registry are indexed under Abdominal Abscess; 5 are open to participants now.

This study's enrollment of 200 is above the median of 105 across 24 interventional studies indexed under Abdominal Abscess.

Browse Abdominal Abscess studies →

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Browse Wyeth studies →All Pfizer studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized male or female subjects over 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Subjects with any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy or follow-up visits could be completed.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants

Study arms

  • Experimental
    1

    armDesc1

    Drug: tigecycline

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical response for all microbiologically evaluable and microbiologically modified intent-to-treat subjects at the test-of-cure visit

Secondary outcomes

  1. Microbiological response at the subject and pathogen level and evaluation of microbiological data, such as decreased susceptibility, response rates by baseline isolate and minimal inhibitory concentration (MIC) values and susceptibility data by isolate

07

Study locations

11 sites
  • Guoxuexiang, Chengdu 610041, China
  • Shengyang, Liaoning 110001, China
  • Hangzhou, Zhejiang, China
  • Beijing, 100044, China
  • Beijing, 100730, China
  • Beijing, 100853, China
  • Shanghai, 200001, China
  • Shanghai, 200040, China
  • Shanghai, 200092, China
  • Shanghai, 200433, China
  • Wuhan, 300063, China
08

References and documents

Publications

  • Chen Z, Wu J, Zhang Y, Wei J, Leng X, Bi J, Li R, Yan L, Quan Z, Chen X, Yu Y, Wu Z, Liu D, Ma X, Maroko R, Cooper A. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis. 2010 Jul 21;10:217. doi: 10.1186/1471-2334-10-217. PubMed 20663130 ↗
  • Fomin P, Koalov S, Cooper A, Babinchak T, Dartois N, De Vane N, Castaing N, Tellado J; 301 And 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. J Chemother. 2008 Oct;20 Suppl 1:12-9. doi: 10.1179/joc.2008.20.Supplement-1.12. PubMed 19036670 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00136201
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
First posted
Aug 26, 2005
Start date
Nov 2005
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Jul 7, 2009

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For China, medinfo@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tigecycline

Other studies in this condition

Abdominal Abscess →

Other studies from this sponsor

Wyeth is now a wholly owned subsidiary of Pfizer →

Start the discussion